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Bypass versus Angioplasty in Severe Ischaemia of the
Leg (BASIL) and the (hoped for) dawn of
evidence-based treatment for advanced limb ischemia
Michael S. Conte, MD, San Francisco, Calif
The Bypass versus Angioplasty in Severe Ischemia of the Leg (BASIL) trial is the only randomized controlled trial (RCT)
to date comparing open surgical bypass with endovascular therapy for severe limb ischemia (SLI). In their initial 2005
publication, the BASIL investigators reported that the main clinical outcomes (overall survival and amputation-free
survival) were no different at 2 years after randomization to angioplasty-first or bypass-first revascularization strategies.
However, beyond 2 years there appeared to be a benefit for open bypass surgery, providing impetus for an extension
study. The final analysis of the long-term outcomes from BASIL is now presented in a set of articles that are reviewed in
this commentary. The benefit of initial randomization to open surgery for patients surviving>2 years (70% of the BASIL
cohort) was confirmed. When outcomes were analyzed by treatment received, patients who had received prosthetic bypass
grafts (25% of the surgical arm) fared much more poorly than those treated with a vein bypass. Patients who underwent
surgical bypass after an initial failed angioplasty also fared significantly worse than those who were treated initially with
bypass surgery. Health-related quality of life measures and costs were not significantly different overall. There are many
controversies surrounding the BASIL trial and its interpretation, which are reviewed herein. These include the choice of
study population, end points examined, and the nature of procedures performed. The BASIL trial confirms the primacy
of open surgical bypass with vein for most patients with SLI and raises questions about the sequelae of failed endovascular
interventions. Further multicenter trials are needed to address the large gap in evidence for treatment selection in this
patient population. (J Vasc Surg 2010;51:69S-75S.)The burden of peripheral arterial-occlusive disease
(PAD) continues to grow, not only in the United States
and Western societies, but across the globe. The epidemi-
ology of PAD has been fueled by aging of the population,
cigarette smoking, and dietary and lifestyle habits com-
bined with dramatic increases in the prevalence of diabetes
mellitus and obesity. At the same time, improved manage-
ment of concomitant coronary artery disease has reduced its
attendant mortality, and thus patients with atherosclerosis
are experiencing greater life expectancy. Beyond just mor-
tality, quality of life, functional status, and resources uti-
lized are critical measures for assessing the effectiveness of
vascular care. The public health effect of this growing
burden of PAD is being experienced acutely in the United
States and many other nations. Together these epidemio-
logic and socioeconomic trends highlight the importance
of safe, durable, and cost-effective therapies for PAD.
Unfortunately, despite the enormity of the patient pop-
ulation at risk, no area of current vascular practice suffers
from as much lack of consensus as does PAD. Unlike
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there are few high-quality randomized controlled trials
(RCTs) to provide level I evidence in support of clinical
decision making in PAD. The continued development of
catheter-based technology has provided an expanding array
of devices, increasing the options for patients but also
amplifying the problem. Within this evidence void, market
forces, turf battles, and industry influences have become
dominating factors in everyday clinical practice. Techni-
cal success, anecdotal evidence, and low quality studies—
disseminated widely by a proliferation of industry-
sponsored “continuingmedical education (CME)” programs—
have substituted for a sobering lack of unbiased clinical
investigation. As a direct result, variability in both treat-
ments applied and outcomes achieved for PAD patients is
exceedingly wide, resulting in inefficient, and not infre-
quently, ineffective care.
Across the PAD spectrum, those with the most ad-
vanced disease (eg, critical limb ischemia [CLI]) constitute
the most vulnerable population. For these patients, thera-
peutic choices have a profound near-term impact on both
life and limb. It is within this broad context that we examine
the importance and relevance of the Bypass versus Angio-
plasty in Severe Ischemia of the Leg (BASIL) trial, the only
RCT to date to directly compare open vs endovascular
revascularization for advanced limb ischemia.
BASIL: SUMMARY OF CHRONOLOGY,
DESIGN, AND PRIMARY FINDINGS
The BASIL trial, sponsored by the United Kingdom
National Institute of Health Research (NIHR) Health Tech-
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1996 to compare the efficacy of balloon angioplasty-first vs
bypass surgery-first treatment strategies in patients with severe
limb ischemia (SLI). Led by Professor Andrew Bradbury, a
vascular surgeon, the BASIL investigators first undertook a
survey of potential participants to examine their views on
the state of clinical equipoise at the time. This study dem-
onstrated a substantial level of disagreement amongst sur-
geons and interventionalists, and may have improved the
subsequent willingness of the trial participants to random-
ize patients.1 The BASIL trial began enrollment in 1999
and eventually involved investigators from 27 centers across
Scotland and England. During a 5-year period, these cen-
ters ultimately randomized 452 patients, meeting their
predefined sample size requirement of 450. A decade later,
we are examining the long-term outcomes of BASIL with a
perspective that is undoubtedly somewhat different than
when the study was first designed.
In 2005 the BASIL trialists reported an analysis of
outcomes out to 2 years that demonstrated no difference in
overall survival (OS) or amputation-free survival (AFS) by
intention-to-treat (ITT) assignment, with surgery being
more expensive in the short-term.2 However, post hoc
analysis demonstrated that beyond 2 years, patients initially
randomized to open bypass surgery had superior clinical
outcomes. This finding was considered significant enough
to warrant funding of an extension study, the results of
which are now presented in a series of manuscripts3-7
comprising this supplement in the Journal of Vascular
Surgery.
The key outcomesmay be summarized as follows. For the
overall follow-up period, there was no significant difference in
OSorAFSby ITTassignment; however, for patients surviving
to 2 years, who comprised 70% of the study cohort, initial
randomization to open bypass was associated with signifi-
cantly improved OS and a trend of increased AFS.
The investigators also now present the trial outcomes
by treatment received, an approach that accounts for early
crossovers but, importantly, loses the unbiased power of
randomization. In this analysis they found that prosthetic
bypass grafts (25% of the surgical group) performed poorly
compared with vein. They also observed that patients who
underwent bypass surgery after an initial failed angioplasty
fared significantly worse than those who underwent bypass
as the initial therapy, suggesting a real potential downside
to failed angioplasty in SLI.
In the interim since the initial 2005 report,muchhas been
made about the design of BASIL and its various limitations.
Yet, the BASIL trial stands alone as a seminal RCT in this
arena and provides an important foundation for developing an
evidence-based approach.What are the implications of BASIL
for current clinical practice, and for future clinical trials? The
discussion that follows will consider various aspects of the
BASIL trial within the context of the existing literature and
attempt to provide perspective on the road ahead to true
evidence-based practice for SLI/CLI.THE BASIL STUDY POPULATION: “SEVERE”
VS “CRITICAL” LIMB ISCHEMIA AND
SELECTION OF THE RANDOMIZED COHORT
The generalizability of any RCT depends on the defi-
nition of the study cohort and its relevance to the broader
disease population and to the pre-existing literature to
which it will be compared. The definition of CLI that
permeates much of the vascular surgery literature is a clin-
ical syndrome including ischemic rest pain, nonhealing
ulceration, and gangrene (Rutherford categories 4 to 6;
Fontaine stages III to IV). Many reports detailing out-
comes of revascularization for CLI used these clinical defi-
nitions alone without hemodynamic criteria. It is recog-
nized that within the Rutherford 4 to 5 categories (rest
pain, minor tissue loss), there is a broad spectrum of hemo-
dynamic severity, including potentially, some patients with
milder degrees of vascular insufficiency. Moreover, the
long-term prognosis for patient survival and limb loss are
directly related to the extent of disease.
More recent consensus statements have thus used a
stricter definition for CLI that includes ankle and toe
pressure threshold levels;8,9 however, there remains signif-
icant debate about the values. The definition is important in
designing prospective clinical trials and is critically impor-
tant for comparing outcomes between data sets.
The BASIL investigators chose to study the broader
population of SLI (Rutherford 4-6), with no absolute
cutoff for ankle/toe pressure. The SLI population is likely
quite representative of the patients undergoing revascular-
ization for “limb salvage” in everyday practice. However,
the true natural history of SLI and CLI has never been
compared, nor have the expected gains from revasculariza-
tion been contrasted. The clinical/hemodynamic stratifica-
tion scheme that was used (rest pain vs tissue loss; ankle
pressure50 vs50 mmHg) ensured that randomization
was equal across the subgroups; however, the trial was not
separately powered for each of these strata. This is relevant,
because the chosen end points of OS and AFS would be
expected to vary significantly across these groups, as would
the relationship between successful revascularization and
these end points. Like all RCTs, the BASIL investigators
were faced with compromises to be made in terms of scope,
feasibility, and costs of their study. In general, the popula-
tion ultimately chosen would seem more favorable for
angioplasty than a true CLI cohort and less likely to suffer
near-term amputation if treatment were to fail.
Beyond the SLI-CLI distinction, the more challenging
aspect of interpreting BASIL relates to how the investiga-
tors applied the criteria of “gray area of clinical equipoise.”
In an audit of several BASIL trial sites, approximately 50%
of all SLI patients were considered suitable for revascular-
ization. Of these, 30% were considered suitable for ran-
domization, and 70% of these were actually enrolled; that
is, approximately 10% of all SLI patients presenting to these
centers.2 All RCTs involve careful selection, and require a
belief in equipoise on the part of both investigator and
patient. However, by choosing not to define specific clinical
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BASIL design left wide latitude to each participating center
that complicates the current interpretation of their find-
ings. The definitions of equipoise may have varied signifi-
cantly by center and over time, and are not known to those
outside the trial.
In the angiogram-scoring manuscript published in this
supplement,5 the investigators provide detailed informa-
tion on the vascular anatomy of the study population. It
uses the Bollinger scoring system, which is unfamiliar to
most readers and re-emphasizes the shortcomings of the
Trans-Atlantic InterSociety Consensus (TASC) scheme for
SLI/CLI patients. In general, the BASIL population had
moderate to severe disease either above or below the knee,
with equal randomization across the ITT groups. Unfortu-
nately, the outcomes data are not analyzed with respect to
specific anatomic patterns of disease. It would be important
to understand if there were specific anatomic predictors of
futility or long-term success, particularly for angioplasty,
where there is such limited good quality data.
Even today, 10 years after BASIL was initiated, there
remains no consensus on whether or where a “gray area of
equipoise” exists for endovascular vs surgical treatment of
SLI/CLI.However, key variables that are already known to
strongly influence the outcome of the procedures under
study—such as TASCD and/or infrapopliteal disease anat-
omy for angioplasty, and vein availability for bypass, should
be specified in the inclusion/exclusion criteria or stratified
in future study designs (see below).
A relevant comparison would be the approach taken in
the carotid surgery RCTs. Surgeons who participated in the
North American Symptomatic Carotid Endarterectomy
Trial (NASCET)10 undoubtedly subselected patients who
met their own interpretation of “equipoise,” but the
greater specificity of the entry criteria (in this case by
defined degree of internal carotid artery stenosis) facilitated
the interpretation of the NASCET results for everyday
practice and also the design of subsequent confirmatory
studies. Looking at coronary artery disease as a second case,
advances in understanding the roles of percutaneous inter-
vention vs bypass surgery have come through carefully
stratified RCTs based on well-defined anatomic and func-
tional criteria.
AFS AS THE PRIMARY EFFICACY ENDPOINT
IN BASIL
The primary goal of revascularization in advanced limb
ischemia is preservation of a functional limb in a surviving
patient. Thus AFS (a composite of limb salvage and sur-
vival) is a critical outcome measure and an appropriate end
point for RCTs. However, is it the best end point for a
direct comparison of revascularization strategies, and what
are the implications of using AFS as the primary end point
in study design?
The underlying premise of limb revascularization is that
improved perfusion will reduce the risk for amputation or
continued symptoms in the treated limb. Although patient
survival is of paramount importance, few practicing vascularsurgeons offer limb revascularization as a potential life-
saving therapy. The primary hypothesis in comparing two
limb revascularization strategies should focus on the
treated limb. A key limitation of AFS as a primary end point
is that most events within the first 2 years—about two-
thirds—are mortality events that are not likely to be prox-
imally related to the comparison of interest. This creates an
important sample size problem for testing a limb-based
hypothesis. Consider the following: over 2 years, if 40% to
45% of patients in a CLI trial experience death or limb loss,
only about one-third of the events will be amputations. Not
all amputations are directly related to treatment failure, and
even when they are, a considerable variability in time is
observed. Of the roughly 15% amputation events2 years,
perhaps 10% of these would have occurred despite success-
ful revascularization (eg, due to unresolved sepsis). This
implies that the expected rate of amputations directly at-
tributable to failed revascularization is about 12% to 15%
over 1 to 2 years; therefore, a 50% relative risk reduction (a
very large effect size) would be equivalent to detecting a
6-7% absolute risk reduction (ie, from 12% to 6%) for
preventable limb loss.
In designing trials using composite end points such as
AFS, investigators make a best guess regarding the mecha-
nism of action of the treatment(s) under study, the antici-
pated effect-size, and the expected rate of related events
within the composite outcome.With a large enough cohort
and a long enough observation time, one would indeed
expect that AFS should correlate with safe and effective
limb revascularization in SLI/CLI. From this perspective
(admittedly different from the philosophy of the BASIL
trialists), I believe that BASIL suffers from a type II error
due to an overestimation of the effects of revascularization
on the primary end point.
An important corollary of this consideration is the
common over-interpretation of “limb salvage” rates from
registry-based reports and nonrandomized studies in PAD.
For example, the Circulase trial,11 which tested the effect of
iloprost in patients with CLI deemed “unreconstructable,”
reported that individuals randomized to the placebo arm
had a 1-year limb salvage rate of 87%. It is useful to keep
such numbers in mind the next time one encounters a
report touting 90% limb salvage for a new graft or device to
treat limb ischemia: Is it significantly different from the
expected natural history?
The second major issue with the use of AFS as the
primary end point is that it ignores clinical events that are of
major importance to the patient and directly attributable to
the initial procedure; namely, reinterventions. The diffi-
culty with reinterventions, as pointed out by the BASIL
authors, is the challenge of incorporating the magnitude
and frequency of these events into an integrated outcome
measure, and the influence of surgical decision making on
the timing and need for secondary procedures. Comparison
of open vs endovascular treatment is further confounded by
established approaches for surveillance and reintervention
of vein grafts on the one hand, and the lack of any consen-
sus in this regard for endovascular therapies. These issues
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magnitude and number of reinterventions per limb saved,
are outcomes that should be measured and reported in
studies comparing revascularization strategies.
In suggesting objective performance goals (OPG) for
CLI treatment, a consensus group, which included the author
and the lead investigator of BASIL, has distinguishedmajor vs
minor reinterventions using a definition which we believe has
clinical relevance.12 Consider that with AFS as the primary
end point in BASIL, it would be possible for a large percent-
age of patients in the endovascular arm to subsequently un-
dergo a bypass graft—resulting in no discernible difference in
the main trial outcome by ITT. Freedom from amputation or
major reintervention, denoted as a major adverse limb event
(MALE) is amoremeaningful primary efficacy end pointwith
a significantly higher rate of treatment-related events, translat-
ing into more predictable power estimation. Analyses from
the OPG dataset12 (http://www.criticallimb.org) confirm
that MALE is more sensitive to factors directly correlating
with quality of the revascularization (eg, poor quality vein
conduit), whereas AFS is primarily correlated with risk factors
for mortality (eg, patient age).
In addition to clinical endpoints such as MALE and
AFS, studies of limb revascularization should incorporate
an objective measure of hemodynamic success. Magnitude
and durability of improved perfusion is a direct measure of
treatment efficacy. Because of the complexities of assessing
patency for endovascular procedures, a global measure such
as ankle or toe pressure index should be included in the end
point definition. One suggestion for defining hemody-
namic failure was made by the Society for Vascular Surgery
(SVS) CLI-OPG working group and included clinical
events (amputation, reintervention), a drop in ankle-
brachial index/toe-brachial index, or imaging evidence of
severe stenosis or occlusion.12 The lack of data on hemo-
dynamic improvement/durability in BASIL in the current
reports is disappointing, and hopefully will be forthcoming
from future analysis.
PATIENT SURVIVAL OUTCOMES IN BASIL
Among the rationales for less invasive therapy in SLI/
CLI, the advanced age and comorbidities of this patient
population is an important consideration. Taken to an
extreme, however, a nihilistic approach has crept into re-
cent debates on this topic. The 2-year survival for patients
enrolled in BASIL was 70%, quite comparable with the
1-year mortality of 15% observed in the Project of Ex-Vivo
Vein Graft Engineering via Transfection (PREVENT) III
trial.13 Although it is acknowledged that RCT cohorts may
not be representative of “real-world” settings, these studies
demonstrate that many, if not most, SLI/CLI patients will
survive beyond 2 to 3 years. Thus treatment durability
beyond 12 months is an important factor to be considered
in RCT design as well as in everyday clinical decision
making.
BASIL confirms the fundamental tradeoff between
long-term benefit and less invasive treatment that perme-
ates clinical judgments in advanced limb ischemia. Theidentification of SLI/CLI patients who have reduced ex-
pected survival would thus provide important information
for optimizing treatment choices. Towards that end, the
BASIL investigators developed amodel to predict mortality
based on data from their study population.7 Schanzer
et al14 have reported a prediction model for AFS from the
PREVENT III trial, which they have also validated exter-
nally (retrospectively) in other multicenter cohorts of CLI
patients. To be useful in clinical practice, however, such
models need to be tested prospectively in similarly defined
cohorts of SLI/CLI patients being considered for revascu-
larization. Until validated in this fashion, these models
should be considered research tools.
SURGICAL OUTCOMES IN BASIL
As noted above, comparisons of the treatment out-
comes in BASIL to other single-center reports and RCTs in
the literature must consider differences in the study popu-
lation as well as in the end points reported. Nonetheless,
the exercise is important to provide context. The outcomes
for vein grafts in BASIL and PREVENT III are compared
in Table I. The overall surgical outcomes reported are not
dissimilar, although the trials differed markedly in their
approach to surveillance and reintervention. Objectively
measured patency and hemodynamic data have not been
reported from BASIL.
The BASIL investigators allowed prosthetic bypass grafts
within the open surgery arm and have discussed the rationale
for this decision. The reported results, that prosthetic bypass
grafts performed poorly in the SLI population, confirm what
might have been expected. Future studies should not assume
homogeneity of open bypass outcomes if prosthetic graft
procedures are included in an undefined proportion; either
outright exclusion or prespecified stratification should be used
to avoid this major source of confounding in open surgical
Table I. Comparison of vein bypass graft outcomes at
1 year between Bypass versus Angioplasty in Severe Ischemia
of the Leg (BASIL) and Project of Ex-Vivo Vein Graft
Engineering via Transfection (PREVENT) IIIa
Outcome
PREVENT III BASIL
(n 605) (n 186)
Survival, % 87 81
Limb salvage, % 90 88
AFS, % 78 72
MALE  POD,
%
76 78
AFS, Amputation-free survival;MALE,major adverse limb event (amputation,
major reintervention inclusive of new bypass surgery, major graft revision,
thrombectomy/thrombolysis); POD, perioperative (30-day) death.
aData source is from the SVS CLI-OPG project (http:/ www.criticallimb.
org). Prosthetic grafts in BASIL were excluded, as were dialysis patients and
grafts treated with the study drug (edifoligide) in PREVENT III.results.
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Much has been made about the nature and quality of
endovascular therapy in BASIL and its relevance to current
practice. Indeed, the use of adjunctive stents, stent-grafts,
laser and atherectomy devices in the leg in the decade since
BASIL was initiated has increased logarithmically, albeit
with minimal if any supporting evidence. In the setting of
rapidly evolving technology, no large clinical trial can ever
test the latest generation of procedures. In addition, the
anatomic spectrum of disease treated in BASIL might be
different from what investigators would consider “equi-
poise” today. Unlike surgical bypass with vein, there is no
consensus, gold-standard endovascular approach for treat-
ing advanced limb ischemia.
An advantage of BASIL is that it provides useful data on
one relatively uniform catheter-based approach in CLI,
namely balloon angioplasty. However, to the extent that
many interventionalists use adjunctive technologies, the out-
come has limited translation to their practice. Again, it is
difficult and perhaps inappropriate to directly compare endo-
vascular outcomes in BASIL to the very few other prospective
trials in SLI/CLI populations (Table II).15,16 However, the
outcomes appear broadly similar to those from recent single-
center series.16 The heterogeneity of endovascular treatments
will remain a challenge to clinical trial design in PAD for the
foreseeable future.
A potentially important finding reported in the “by
treatment received” analysis is the adverse effect of failed
angioplasty on subsequent bypass surgery outcomes. Fur-
ther elucidation of how this may have occurred—and
whether it was causally related— would be important.
Nonetheless, it has frequently been suggested that a failed
endovascular attempt doesn’t burn any bridges, an asser-
tion that is now directly contradicted by the observed
outcomes in BASIL. Onemay reasonably extrapolate that if
such is the case for simple angioplasty, it may well be even
more so with the use of adjunctive stents, covered stents,
etc. Future studies will need to examine the sequelae of
endovascular failures more closely and determine if surveil-
lance or earlier reintervention would improve subsequent
Table II. Endovascular outcomes at 1 year in Bypass
versus Angioplasty in Severe Ischemia of the Leg
(BASIL) compared with selected reports in severe limb
ischemia and critical limb ischemia patients
Outcome
BASIL Laird et al15 Giles et al16
(n  217) (n  145) (n  163)
Survival, % 81 92a 80
Limb salvage, % 86 93a 84
AFS, % 71 82a N/A
MALE  POD, % 69 N/A N/A
AFS, Amputation-free survival; MALE, major adverse limb event (amputa-
tion, major reintervention inclusive of new bypass surgery, major graft
revision, thrombectomy/thrombolysis);N/A, not applicable; POD, periop-
erative (30-day) death.
aReported at 6 months only.outcomes.HEALTH-RELATED QUALITY OF LIFE AND
COST IMPLICATIONS
BASIL confirms that patients with SLI have markedly
impaired quality of life (QOL), and care of these patients is
costly and resource-intensive. Overall, QOL and cost
were not significantly different for the initial randomized
treatments. However, it would be of great interest to
understand the factors associated with QOL and re-
source utilization within the BASIL study population. In
the PREVENT III cohort,17 graft failure was a potent
determinant of both; that is, patients with sustained pa-
tency of their bypass experienced greater improvements in
QOL and required less subsequent hospital care, after
controlling for other key patient and procedure-related
variables.
IMPLICATIONS OF BASIL FOR CURRENT
CLINICAL PRACTICE
The results of BASIL suggest that patients with SLI
who are candidates for revascularization and likely to
live 2 years, which constituted 70% of the trial popula-
tion, are better served by vein bypass surgery as their initial
procedure. Prosthetic bypass grafts perform poorly in SLI/
CLI, and should not be used as primary treatment. Failure
after angioplasty may impart increased risk for subsequent
bypass surgery; therefore, endovascular treatment should
not be regarded as a risk-free choice for the patient. BASIL
confirms that, regardless of initial treatment, patients with
advanced limb ischemia undergo complex journeys with
many reinterventions and require longitudinal care from
dedicated specialists. It also confirms that high-quality
open bypass surgery remains a critical element of the ther-
apeutic armamentarium for limb preservation. Efforts to
understand the variability in quality of this benchmark
procedure in vascular surgery would lead to improved
care—and reduced costs—for the SLI/CLI patient. Bypass
surgery outcomes should be considered a key quality mea-
sure for specialized centers in advanced limb ischemia.
Optimal care for the patient with advanced limb isch-
emia in 2010 includes the use of proven atheroprotective
medications such as antiplatelet agents, statins, and antihy-
pertensive drugs in accordance with current consensus
guidelines.18 BASIL and PREVENT III both document
the need for considerable improvement in this arena, which
is likely to have a significant positive effect on long-term
survival. In addition, healing of wounds and preservation of
a functional foot requires broad expertise on the part of the
limb salvage team. Longitudinal care of the SLI/CLI pa-
tient is best provided by a multidisciplinary team led by a
dedicated vascular specialist.
IMPORTANCE AND IMPLICATIONS FOR
FUTURE RCTS
A concerted effort is urgently needed on the part of
surgeons, interventionalists, and governmental and indus-
try sponsors to conduct a series of multicenter studies
comparing the effectiveness of treatments for advanced
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artery disease in the 1990s, resulting in the execution of
pivotal trials in both North America and Europe that
greatly improved evidence-based practice. BASIL has pro-
vided the important first example and has highlighted
challenges in study design that should inform subsequent
investigators. RCTs provide the highest level of clinical
evidence and should be strongly supported by the vascular
surgery community and its representative professional so-
cieties. What follows are a few recommendations for how
future “BASIL-like” trials might be designed.
Definition of a CLI cohort should follow recom-
mended consensus guidelines.19 The presence of tissue loss
vs rest pain has a powerful effect on outcomes such as AFS,
and these groups should be separately powered as distinct
clinical arms.
Anatomy of the occlusive disease and conduit availabil-
ity, as noted, exert important influences on the results of
endovascular and open surgical interventions. Further-
more, these are critical factors used by treating surgeons in
everyday practice as they attempt to weigh the risks and
benefits of a revascularization approach. Therefore, trial de-
sign should incorporate these key factors in a meaningful and
clearly defined way. One suggestion might be to limit inclu-
sion to patients who are considered likely to have an adequate
quality saphenous vein available for bypass. Stratification of
the clinical study arms by an anatomic criterion (eg, hemody-
namically significant infrapopliteal disease that would require
bypass to a tibial or pedal level) would ensure balanced ran-
domization and adequate power to detect outcome differ-
ences across these important subgroups as well.
On the basis of the discussion above, I believe the best
primary end point for a comparative CLI trial would go
beyond limb loss to consider reintervention and its magni-
tude (ie, MALE), and also incorporate periprocedural (30-
day) mortality. AFS and hemodynamic failure should be
key secondary end points in such trials.
Finally, an important consideration for future trials is
whether “open” vs “endo” is really the defining compari-
son in an era of increasing hybrid approaches and devices
that are not necessarily designed as stand-alone therapies.
The more clearly we define the role—or lack thereof—for
specific procedures, the more we will be able to optimize
care (and with it, cost efficiency) for the individual patient.
No single trial can accomplish all of these goals, which is
why a sustained effort on the part of all stakeholders is
required.
DEVICE DEVELOPMENT AND OPGS FOR CLI
The challenges of executing adequately poweredmulti-
center RCTs in advanced limb ischemia have been well
demonstrated by BASIL and the foregoing discussion.
Although such trials provide the highest level of medical
evidence, they represent a significant hurdle for the contin-
ued development of technology for advanced PAD. The
time and cost needed to complete such studies could be a
disincentive to innovation. TheUS Food andDrug Admin-
istration (FDA), the agency that regulates the entry ofdrugs and devices into the marketplace, has considered
alternative approaches for evaluating new technology based
on historic benchmarks. Thus Objective Performance Cri-
teria (OPC) have been developed for devices such as cardiac
valve prostheses, based on a large volume of high-quality
data that allow for single-arm trial designs in premarket
approval studies.20 Historical data of lesser quantity or
quality may be used to define an initial set of OPG which,
with time and further validation, may evolve into OPC.
Recently, OPG have been suggested for femoropopliteal
stents, and their use in FDA-approved clinical trial designs
may be a reasonable alternative to randomized studies.21
The recent availability of high-quality data on open
surgical bypass from several multicenter trials, including
PREVENT III, BASIL, and Circulase, created an opportu-
nity to define OPG for the treatment of CLI. A working
group charged by the SVS undertook this initiative in 2008
and reported their initial recommendations in a recent
publication.12 Pooled data from these trials were analyzed
to develop expected outcomes for vein bypass surgery as the
relevant standard for comparison. The group endorsed a set
of three safety and six efficacy goals for endovascular devices
targeting the CLI population. They also defined specific
high-risk subgroups in CLI: clinical high-risk (age 80
years and tissue loss), anatomic high-risk (infrapopliteal
disease), and conduit high-risk (lack of adequate quality
great saphenous vein) for which distinct OPG were gener-
ated. The authors compared existing data on endovascular
treatments from the literature as well as the angioplasty arm
of BASIL to the defined OPG. For example, the angio-
plasty results in BASIL would not have met the key efficacy
OPG for all-comers with CLI, but would have met the
desired targets for patients lacking good quality vein.
The relevance of these OPG for CLI will need to be
established by subsequent device trials, as well as comparison
with real-world experiences. The continued refinement of
these benchmarks would be improved by incorporation of
high-quality endovascular data from prospective trials using
similar measures. The cooperation of industry and investiga-
tors from all disciplines will be critical to promote the further
development and use ofOPG for device development in CLI.
Summary analyses from the SVS working group are publicly
available at http://www.criticallimb.org.
CONCLUSIONS
The BASIL trial is a landmark effort that has launched the
era of evidence-based practice for advanced limb ischemia.
The need for global improvement in all aspects of care for the
SLI/CLI patient—from medical management through out-
comes of both endovascular and open procedures—is clear.
BASIL confirms the primacy of open surgical bypass using
autogenous vein as the standard for comparison in SLI/CLI.
It also refutes the espousal of a nihilistic approach for the large
majority of these patients and highlights the potential risks of
a short-term therapeuticmentality. This seminal trial hasmade
a critical step forward in developing high-quality data to guide
decision making in the field. We are all indebted to the
JOURNAL OF VASCULAR SURGERY
Volume 51, Number 10S Conte 75Spatients and investigators of BASIL for their commitment to
this goal.
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